FDA Approved: AMBRISENTAN — Supplemental Application (Cipla USA Inc.)

View source ↗

Summary

The FDA approved Cipla USA Inc.'s supplemental application for ambrisentan, allowing the generic version to be marketed in the United States for pulmonary arter…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• Ambrisentan (Ambrisentan)

Snippet

SUPPL AP for AMBRISENTAN (AMBRISENTAN)